Extended Release Plastic Matrix for Transdermal Bio-Active Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods of bio-active agent administration, such as oral and transdermal delivery, face challenges like first-pass metabolism, uneven absorption, and short-acting effects, necessitating a method for extended and consistent release of therapeutic and nutritional agents.
Innovation Solution
Development of an extended release plastic matrix (ERPM) comprising a structural polymer, liquid-binding material, and a carrier liquid, where bio-active agents are embedded as solid islands, allowing for controlled release through the skin over an extended period, typically a week or more, via a therapeutically effective rate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral administration is used to deliver bio-active agents, then the administration route is simple and common, but first-pass metabolism occurs causing greatly reduced concentration before reaching systemic circulation
Solution Approach 1:
The patent uses the skin as an intermediary delivery route to bypass the gastrointestinal tract and liver, allowing bio-active agents to enter systemic circulation directly through transdermal absorption, thereby avoiding first-pass metabolism while maintaining ease of administration
Solution Approach 2:
The invention changes the administration parameter from oral to transdermal route, fundamentally altering the pharmacokinetic profile by eliminating hepatic first-pass metabolism and achieving higher systemic bioavailability
2Ease of operation
If oral administration is used to deliver bio-active agents, then the administration method is straightforward, but absorption occurs as a bolus resulting in peaks and troughs of systemic concentration causing unwanted side effects
Solution Approach 1:
The transdermal delivery system provides continuous release and absorption of bio-active agents through the skin, eliminating the bolus absorption pattern that causes concentration peaks and troughs, thereby maintaining stable systemic levels without unwanted side effects
Solution Approach 2:
The bio-active agents are pre-loaded into the plastic material matrix before application, enabling controlled and sustained release over time rather than immediate bolus release, which stabilizes concentration profiles
3Quantity of substance
If creams and lotions are used for transdermal delivery, then the skin barrier is bypassed increasing bioavailability, but the formulation is short-acting and may be accidentally rubbed or washed off resulting in difficulty achieving consistent bloodstream concentration
Solution Approach 1:
The patent employs a composite plastic material system consisting of a polymer matrix embedded with bio-active agents and liquid-binding materials, creating a durable formulation that maintains structural integrity on skin while enabling sustained release, unlike conventional creams and lotions
Solution Approach 2:
The plastic material forms a flexible matrix that adheres to the skin surface, providing a durable carrier that resists being rubbed or washed off while allowing transdermal penetration, thereby extending duration of action compared to traditional cream formulations
4Quantity of substance
If creams and lotions are used for transdermal delivery, then the skin barrier is bypassed, but consistent or effective bloodstream concentration is difficult to achieve due to short-acting nature
Solution Approach 1:
The embedded bio-active agents in the plastic material provide continuous transdermal release and absorption over an extended period, ensuring reliable and consistent bloodstream concentration rather than the intermittent delivery characteristic of short-acting creams and lotions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ERPM ensures sustained and consistent transdermal absorption of bio-active agents, providing therapeutic benefits for an extended duration without peak and trough effects, enhancing bioavailability and patient compliance.
Implementation Method 1
a liquid-binding material embedded within the structural polymer, a carrier liquid absorbed within the liquid-binding material
Implementation Method 2
the carrier liquid is capable of dissolving the bio-active agent at room or body temperature
Implementation Method 3
the plastic material being formulated for an extended release of the embedded one or more bio-active agents
Data Source
AI summary
A plastic material for extended release of a bio-active agent, the plastic material comprising a structural polymer, at least one bio-active ingredient embedded within the structural polymer as solid islands, a liquid binding material embedded within the structural polymer as granules, and a carrier liquid absorbed within the liquid-absorbent material. The carrier liquid may be sufficiently non-compatible with the structural polymer so that at least a portion of the carrier liquid is released from the liquid-absorbent material through the structural polymer to an outer surface of the plastic material over a period of time, such as a week or more, a month or more, or about three months. The bio-active agent comprised in the at least one bio-active ingredient may be sufficiently soluble in the carrier liquid at room or body temperature so that the carrier liquid released to the outer surface comprises the bio-active agent in solution.